Combination therapy with sorafenib and S-1 for renal cell carcinoma producing granulocyte colony-stimulating factor

We present the first case report of the use of sorafenib and S-1 for the treatment of renal cell carcinoma (RCC) producing granulocyte colony-stimulating factor (G-CSF). This entity is clinically rare and has a poor outcome. A 78-year-old Japanese man presented with macrohematuria, left flank pain,...

Full description

Saved in:
Bibliographic Details
Published in:International journal of clinical oncology 2011-06, Vol.16 (3), p.275-278
Main Authors: Kyono, Yoko, Takayama, Tatsuya, Kinoshita, Mana, Kurita, Yutaka, Mugiya, Soichi, Baba, Satoshi, Ozono, Seiichiro
Format: Article
Language:English
Subjects:
Aged
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Benzenesulfonates - administration & dosage
Cancer Research
Carcinoma, Renal Cell - drug therapy
Carcinoma, Renal Cell - metabolism
Carcinoma, Renal Cell - pathology
Case Report
Chemotherapy
Drug Combinations
Granulocyte Colony-Stimulating Factor - biosynthesis
Granulocyte Colony-Stimulating Factor - blood
Granulocyte Colony-Stimulating Factor - drug effects
Granulocyte Colony-Stimulating Factor - urine
Humans
Kidney Neoplasms - drug therapy
Kidney Neoplasms - metabolism
Kidney Neoplasms - pathology
Kidneys
Leukocytosis
Male
Medical Futility
Medicine
Medicine & Public Health
Niacinamide - analogs & derivatives
Oncology
Oxonic Acid - administration & dosage
Pathology
Phenylurea Compounds
Pyridines - administration & dosage
Surgical Oncology
Tegafur - administration & dosage
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:We present the first case report of the use of sorafenib and S-1 for the treatment of renal cell carcinoma (RCC) producing granulocyte colony-stimulating factor (G-CSF). This entity is clinically rare and has a poor outcome. A 78-year-old Japanese man presented with macrohematuria, left flank pain, and a palpable mass. Laboratory data showed marked leukocytosis with increased serum and urinary G-CSF. The histopathological diagnosis was unclassified RCC. New combination therapy with sorafenib and S-1 exerted a therapeutic effect and apparently decreased serum and urinary G-CSF levels, although the patient died of gastrointestinal perforation. The use of combined sorafenib and S-1 may be worthy of consideration in the treatment of RCC producing G-CSF.
ISSN:1341-9625
1437-7772
DOI:10.1007/s10147-010-0126-x